Orforglipron is an oral small-molecule GLP-1 monoagonist that is investigational and not yet FDA-approved as of May 2026
Key protective strategies include: Pre-treatment ophthalmologic evaluation : Establish baseline retinal status before initiating GLP-1 therapy, particularly in patients with diabetes duration exceeding 10 years or poor prior glycemic control Individualized medication titration : Consider a more gradual dose escalation approach to avoid precipitous drops in blood glucose for patients with advanced diabetic retinopathy, in coordination with ophthalmology care Appropriate monitoring : Discuss with your healthcare provider whether more frequent eye examinations are needed based on your individual risk factors and baseline retinal status Prompt reporting of visual symptoms : Contact your healthcare provider immediately if you experience sudden vision loss, new or dense floaters, flashing lights, a "curtain" over your vision, eye pain with vision changes, or any sudden vision disturbance Patients without pre-existing diabetic retinopathy can generally follow standard eye examination schedules and do not require additional ophthalmologic monitoring solely due to GLP-1 use
This pharmacological design depends entirely on gradual absorption from fatty tissue
The FDA shortage database listed semaglutide as in shortage from March 2022 until February 2025, allowing legal compounding under federal regulations
"People that bleach their skin have brown spots
Skin integrity Avoid areas with bruising, scarring, stretch marks, lipohypertrophy (thickened or lumpy skin from repeated injections), active skin infections, or broken skin
